Remdesivir, Gilead Sciences’ drug, could be under consideration to be added to the classified US Strategic National Stockpile (SNS), as well as individual states’ stockpiles, in the event donated doses exhaust and Covid-19 cases outstrip supply.
According to a 1 May company press release, Gilead’s donated of 1.5 million individual remdesivir doses adds up to more than 140,000 treatment courses (assuming a 10-day treatment course). Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
